Article info
PDFLetters
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
- Correspondence to Professors Chunde Bao and Qiang Guo, Rhematology Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.145, Shangdong (c) Road, 200001, Shanghai, China; baochunde_1678{at}126.com and marquisjerry{at}126.com
Citation
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
Publication history
- Received January 23, 2014
- Revised March 16, 2014
- Accepted March 22, 2014
- First published April 16, 2014.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions